Results 71 to 80 of about 141 (84)
Some of the next articles are maybe not open access.
Diabetes
Introduction and Objective: Clinical evidence suggests that integrating Dual Amylin and Calcitonin Receptor Agonism (DACRA) with incretin and glucagon receptor signaling may provide a synergistic mechanism for appetite suppression, weight loss, and improved insulin sensitivity.
WARREN WEN +3 more
exaly +2 more sources
Introduction and Objective: Clinical evidence suggests that integrating Dual Amylin and Calcitonin Receptor Agonism (DACRA) with incretin and glucagon receptor signaling may provide a synergistic mechanism for appetite suppression, weight loss, and improved insulin sensitivity.
WARREN WEN +3 more
exaly +2 more sources
American Journal of Physiology - Endocrinology and Metabolism, 2023 Dual amylin and calcitonin receptor agonists (DACRAs) are effective treatments for obesity and type 2 diabetes (T2D). They provide beneficial effects on body weight, glucose control, and insulin action.
Morten Karsdal +2 more
exaly +2 more sources
Dynamic programming of flights based on stochastic demands [PDF]
, 2015 The definition of the flights schedule is one of the major planning activities that are carried out in an airline. The result of the definition of this schedule has implications that transcend the operational sphere and becomes a determining factor to ...
Pau Fonseca Casas, Josep Casanovas
exaly +2 more sources
American Journal of Physiology - Endocrinology and Metabolism, 2017 Amylin and GLP-1 agonism induce a well-known anorexic effect at dose initiation, which is managed by dose escalation. In this study we investigated how to optimize tolerability while maintaining efficacy of a novel, highly potent dual amylin and ...
Morten Karsdal +2 more
exaly +2 more sources
1995-P: Optimization of DACRA Dosing Frequency—The Balance between Efficacy and Tolerability
Diabetes, 2019Potent dual amylin and calcitonin receptor agonists (DACRAs) are novel candidates for treatment of T2D and obesity due to their beneficial effects on body weight, blood glucose and insulin sensitivity. Notably, DACRAs activate the receptors for a prolonged time period resulting in metabolic effects superior to those of amylin.
ANNA T. LARSEN +4 more
openaire +1 more source
2016-P: High Dose DACRA Treatment Improves Glucose Homeostasis, without Additional Weight Loss
Diabetes, 2019KBP is a Dual Amylin and Calcitonin Receptor Agonist (DACRA). DACRAs have shown efficacy on weight loss and glucose control in rats. However, it is unclear whether the maximum effect has been reached. High Fat Diet (HFD, 60% fat) fed male Sprague-Dawley rats entered a dose escalation regimen ending at 5 (normal dose), 50 or 500 µg/kg daily KBP (n=10 ...
NINA SONNE +4 more
openaire +1 more source
American Journal of Physiology - Endocrinology and MetabolismLong-acting dual amylin and calcitonin receptor agonists (DACRAs) are novel candidates for the treatment of type 2 diabetes and obesity due to their beneficial effects on body weight, glucose control, and insulin action.
Morten Karsdal +2 more
exaly +2 more sources